PCA3 Urine mRNA Testing for Prostate Carcinoma: Patterns of Use by Community Urologists and Assay Performance in Reference Laboratory Setting

Urology

Volumn 73, Issue 2, 2009, Pages 363-368

  Shappell, Scott B ^a   Fulmer, John ^a   Arguello, David ^b   Wright, Brian S ^b   Oppenheimer, Jonathan R ^c   Putzi, Mathew J ^c  

^a Molecular Oncology Diagnostic Laboratory   (United States)

^b Molecular Profiling Institute   (United States)

^c Oppenheimer Urologic Reference Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER GENE 3; PROSTATE CARCINOMA; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; TUMOR GENE; URINALYSIS;

ANTIGENS, NEOPLASM; HUMANS; LABORATORIES; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; RNA, MESSENGER; UROLOGY;

EID: 58649113410     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.08.459     Document Type: Article

References (20)

1. Wilson S.S., and Crawford E.D. Screening for prostate cancer: Current recommendations. Urol Clin North Am 31 (2004) 219-226
2. Thompson I.M., Bermejo C., Hernandez J., et al. Screening for prostate cancer: Opportunities and challenges. Surg Oncol Clin North Am 14 (2005) 747-760
3. Shappell S.B. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol 10 (2008) 44-69
4. Bussemakers M.J.G., van Bokhoven A., Verhaegh G.W., et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
5. PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
6. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16
7. Tinzl M., Marberger M., Horvath S., et al. DD3(PCA3) RNA analysis in urine-A new perspective for detecting prostate cancer. Eur Urol 46 (2004) 182-187
8. Fradet Y., Saad F., Aprikian A., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64 (2004) 311-315
9. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
10. van Gils M.P.M.Q., Hessels D., van Hooij O., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939-943
11. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
12. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407-2411
13. Deras I.L., Aubin S.M., Blase A., et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
14. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1810
15. Epstein J.I., and Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol 175 (2006) 820-834
16. Girasole C.R., Cookson M.S., Putzi M.J., et al. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: Implications for cancer detection and biopsy strategy. J Urol 175 (2006) 929-933
17. Djavan B., Remzi M., and Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am 30 (2003) 253-262
18. Presti J.C.J. Prostate biopsy strategies. Nat Clin Pract Urol 4 (2007) 505-511
19. Griffin C.R., Yu X., Loeb S., et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 178 (2007) 860-863
20. Popa I., Fradet Y., Beaudry G., et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 20 (2007) 1121-1127